Increased Tc22 and Treg/CD8 Ratio Contribute to Aggressive Growth of Transplant Associated Squamous Cell Carcinoma

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Shali ^a   Fujita, Hideki ^b   Mitsui, Hiroshi ^b   Yanofsky, Valerie R ^c   Fuentes Duculan, Judilyn ^b   Pettersen, Julia S ^d   Suárez Fariñas, Mayte ^b   Gonzalez, Juana ^b   Wang, Claire Q F ^b   Krueger, James G ^b   Felsen, Diane ^d   Carucci, John A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; KI 67 ANTIGEN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TC22 CELL; TRANSPLANT ASSOCIATED SQUAMOUS CELL CARCINOMA; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ANTIGENS, CD3; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCOMPETENCE; INTERLEUKINS; ORGAN TRANSPLANTATION; PHOSPHOPROTEINS; RECEPTORS, INTERLEUKIN; SKIN; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84877114418     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062154     Document Type: Article

References (62)

1. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS, (2000) Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 143: 513-519.
2. Carucci JA, (2004) Cutaneous oncology in organ transplant recipients: meeting the challenge of squamous cell carcinoma. J Invest Dermatol 123: 809-816.
3. Berg D, Otley CC (2002) Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 47: 1-17; quiz 18-20.
4. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, et al. (2007) CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178: 5595-5605.
5. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
6. Rosenberg SA, (2005) Cancer immunotherapy comes of age. Nature clinical practice Oncology 2: 115.
7. Tamai H, Watanabe S, Zheng R, Deguchi K, Cohen PA, et al. (2008) Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin Immunol 127: 66-77.
8. Topalian SL, Weiner GJ, Pardoll DM, (2011) Cancer immunotherapy comes of age. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 4828-4836.
9. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, et al. (2011) Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 131: 1322-1330.
10. Wolk K, Witte E, Witte K, Warszawska K, Sabat R, (2010) Biology of interleukin-22. Seminars in immunopathology 32: 17-31.
11. Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P, et al. (2010) Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5: e14108.
12. Chung Y, Yang X, Chang SH, Ma L, Tian Q, et al. (2006) Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 16: 902-907.
13. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, et al. (2009) IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123: 1244-1252 e1242.
14. Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, et al. (2000) Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 275: 31335-31339.
15. Pan H, Hong F, Radaeva S, Gao B, (2004) Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 1: 43-49.
16. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, et al. (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36: 1309-1323.
17. Boniface K, Guignouard E, Pedretti N, Garcia M, Delwail A, et al. (2007) A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 150: 407-415.
18. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648-651.
19. Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, et al. (2012) Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-A Swedish population-based study. Int J Cancer.
20. Warner CL, Cockerell CJ, (2011) The new seventh edition American Joint Committee on Cancer staging of cutaneous non-melanoma skin cancer: a critical review. American journal of clinical dermatology 12: 147-154.
21. Ikeda H, Old LJ, Schreiber RD, (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109.
22. Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC, (2000) IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun 1: 488-494.
23. Dumoutier L, Louahed J, Renauld JC, (2000) Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 164: 1814-1819.
24. Levy DE, Darnell JE Jr, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
25. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, et al. (2004) Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114: 720-728.
26. Sano S, Chan KS, Kira M, Kataoka K, Takagi S, et al. (2005) Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res 65: 5720-5729.
27. Chan KS, Sano S, Kataoka K, Abel E, Carbajal S, et al. (2008) Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 27: 1087-1094.
28. Kim DJ, Angel JM, Sano S, DiGiovanni J, (2009) Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 28: 950-960.
29. UNOS (2012) Database. www.UNOSORG.
30. Euvrard S, Kanitakis J, Claudy A, (2003) Skin cancers after organ transplantation. N Engl J Med 348: 1681-1691.
31. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, et al. (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40: 177-186.
32. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65: 263-279; quiz 280.
33. Zwald FO, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65: 253-261; quiz 262.
34. Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, et al. (2011) The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4: 444-453.
35. Ladstein RG, Bachmann IM, Straume O, Akslen LA, (2010) Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10: 140.
36. Patel GK, Yee CL, Terunuma A, Telford WG, Voong N, et al. (2012) Identification and characterization of tumor-initiating cells in human primary cutaneous squamous cell carcinoma. J Invest Dermatol 132: 401-409.
37. Zhang N, Pan HF, Ye DQ, (2011) Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Molecular and cellular biochemistry 353: 41-46.
38. Witte E, Witte K, Warszawska K, Sabat R, Wolk K, (2010) Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine & growth factor reviews 21: 365-379.
39. Jabbari A, Johnson-Huang LM, Krueger JG, (2011) Role of the immune system and immunological circuits in psoriasis. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia 146: 17-30.
40. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, et al. (2006) Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126: 869-881.
41. Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R, (2011) Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 4: 9-19.
42. Bard JD, Gelebart P, Anand M, Amin HM, Lai R, (2008) Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 22: 1595-1603.
43. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, et al. (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54: 900-909.
44. Nagalakshmi ML, Rascle A, Zurawski S, Menon S, de Waal Malefyt R, (2004) Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 4: 679-691.
45. Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, Muhl H, (2007) The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282: 16006-16015.
46. Curd LM, Favors SE, Gregg RK, (2012) Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 168: 192-199.
47. Toes RE, Ossendorp F, Offringa R, Melief CJ, (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189: 753-756.
48. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, et al. (2012) Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer. Am J Clin Oncol.
49. Yu P, Fu YX, (2006) Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86: 231-245.
50. Rutella S, Lemoli RM, (2004) Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett 94: 11-26.
51. Beyer M, Schultze JL, (2006) Regulatory T cells in cancer. Blood 108: 804-811.
52. Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, et al. (2006) In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107: 3940-3949.
53. Thornton AM, Shevach EM, (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188: 287-296.
54. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, et al. (2001) Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98: 2736-2744.
55. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, et al. (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24: 5373-5380.
56. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, et al. (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326-8331.
57. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949.
58. Guba M, Graeb C, Jauch KW, Geissler EK, (2004) Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 77: 1777-1782.
59. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S, (2008) Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 8: 2192-2198.
60. Bluth MJ, Zaba LC, Moussai D, Suarez-Farinas M, Kaporis H, et al. (2009) Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 129: 2451-2462.
61. Kaporis HG, Guttman-Yassky E, Lowes MA, Haider AS, Fuentes-Duculan J, et al. (2007) Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 127: 2391-2398.
62. Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, Nograles KE, Pierson KC, et al. (2010) A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130: 2412-2422.